
We claim:

1. A compound having the structural formula



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

3. A compound of claim 1 for treating central nervous system diseases.

4. A compound of claim 1 for treating Parkinson's Diseases, Extra-Pyramidal Syndrome, restless leg syndrome, essential tremor, Huntington's Disease, attention deficit hyperactivity disorder, cognitive impairment, negative symptoms of schizophrenia, depression, stroke or psychoses.

5. A compound of claim 1 for treating Parkinson's Disease, Extra-Pyramidal Syndrome, restless legs syndrome or attention deficit hyperactivity disorder.

6. A pharmaceutical composition comprising a combination of the compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.

7. A pharmaceutical composition of claim 6 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.

8. A pharmaceutical composition of claim 6 or claim 7 for treating Parkinson's disease.

9. The use of a compound of claim 1 in the manufacture of a medicament for treating central nervous system diseases, wherein the central nervous system diseases are Parkinson's Diseases, Extra-Pyramidal Syndrome, restless leg syndrome, essential tremor, Huntington's Disease, attention deficit hyperactivity disorder, cognitive impairment, negative symptoms of schizophrenia, depression, stroke or psychoses.

10. The use of a compound of claim 1 in the manufacture of a medicament for treating Parkinson's Disease, Extra-Pyramidal Syndrome, restless legs syndrome or attention deficit hyperactivity disorder.

11. The use of the pharmaceutical composition of claim 6 or claim 7 in the manufacture of a medicament for treating Parkinson's disease.

12. The use of claim 10, wherein the medicament further comprises a tricyclic antidepressant, lithium or an anticonvulsant.

13. The use of a compound of claim 1, in the manufacture of a medicament for treating or preventing RLS or PLMS.

14. The use of claim 13, wherein the medicament further comprises another agent selected from the group consisting of levodopa/carbidopa, levodopa/ benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant and iron.

15. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat Parkinson's Disease, wherein one container comprises a pharmaceutical composition comprising an effective amount

of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of an agent useful in the treatment of Parkinson's disease.

16. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS caused by treatment with antipsychotic agent, wherein one container comprises a pharmaceutical composition comprising an effective amount of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of an antipsychotic agent.

17. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, wherein one container comprises a pharmaceutical composition comprising an effective amount of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of a tricyclic antidepressant, lithium or an anticonvulsant.

18. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat RLS or PLMS, wherein one container comprises a pharmaceutical composition comprising an effective amount of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron.


19. The use of claim 9, wherein the medicament further comprises an antipsychotic agent.

20. The use of a compound of claim 1, in the manufacture of a medicament for treating attention deficit hyperactivity disorder, depression, stroke or psychoses.

21. The compound of claim 1 for use in the treatment of primary (idiopathic) dystonia induced by a tricyclic antidepressant, lithium, an anticonvulsant or cocaine.

We claim:

1. A compound having the structural formula



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

3. A compound of claim 1 for treating central nervous system diseases.

4. A compound of claim 1 for treating Parkinson's Diseases, Extra-Pyramidal Syndrome, restless leg syndrome, essential tremor, Huntington's Disease, attention deficit hyperactivity disorder, cognitive impairment, negative symptoms of schizophrenia, depression, stroke or psychoses.

5. A compound of claim 1 for treating Parkinson's Disease, Extra-Pyramidal Syndrome, restless legs syndrome or attention deficit hyperactivity disorder.

6. A pharmaceutical composition comprising a combination of the compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.

7. A pharmaceutical composition of claim 6 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.

8. A pharmaceutical composition of claim 6 or claim 7 for treating Parkinson's disease.

9. The use of a compound of claim 1 in the manufacture of a medicament for treating central nervous system diseases, wherein the central nervous system diseases are Parkinson's Diseases, Extra-Pyramidal Syndrome, restless leg syndrome, essential tremor, Huntington's Disease, attention deficit hyperactivity disorder, cognitive impairment, negative symptoms of schizophrenia, depression, stroke or psychoses.

10. The use of a compound of claim 1 in the manufacture of a medicament for treating Parkinson's Disease, Extra-Pyramidal Syndrome, restless legs syndrome or attention deficit hyperactivity disorder.

11. The use of the pharmaceutical composition of claim 6 or claim 7 in the manufacture of a medicament for treating Parkinson's disease.

12. The use of claim 10, wherein the medicament further comprises a tricyclic antidepressant, lithium or an anticonvulsant.

13. The use of a compound of claim 1, in the manufacture of a medicament for treating or preventing RLS or PLMS.

14. The use of claim 13, wherein the medicament further comprises another agent selected from the group consisting of levodopa/carbidopa, levodopa/ benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant and iron.

15. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat Parkinson's Disease, wherein one container comprises a pharmaceutical composition comprising an effective amount

of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of an agent useful in the treatment of Parkinson's disease.

16. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent EPS caused by treatment with antipsychotic agent, wherein one container comprises a pharmaceutical composition comprising an effective amount of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of an antipsychotic agent.

17. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat or prevent dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant, wherein one container comprises a pharmaceutical composition comprising an effective amount of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of a tricyclic antidepressant, lithium or an anticonvulsant.

18. A kit comprising, in separate containers in a single package, pharmaceutical compositions for use in combination to treat RLS or PLMS, wherein one container comprises a pharmaceutical composition comprising an effective amount of the compound of formula I in a pharmaceutically acceptable carrier, and another container comprises a pharmaceutical composition comprising an effective amount of levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron.

19. The use of a compound of claim 1, in the manufacture of a medicament for treating attention deficit hyperactivity disorder, depression, stroke or psychoses.

20. The compound of claim 1 for use in the treatment of primary (idiopathic) dystonia induced by a tricyclic antidepressant, lithium, an anticonvulsant or cocaine.